This inventor holds 1 USPTO granted patent. Top assignees: Icahn School of Medicine at Mount Sinai, Johns Hopkins University. Active years: 2006.
Company Filing History:
1 out of 535 
1 out of 3,795 
Years Active: 2006
Title: Ararat Abloogu: Innovator in Protein Kinase Inhibitors
Introduction
Ararat Abloogu is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biochemistry, particularly in the development of protein kinase inhibitors. His work has implications for anti-cancer therapies and biological tools in cell signaling.
Latest Patents
Abloogu holds a patent for bisubstrate inhibitors of kinases. This patent focuses on protein kinase inhibitors that have applications as anti-cancer therapeutic agents. The potent and selective bisubstrate inhibitors for the insulin receptor tyrosine kinase are based on a phosphoryl transfer mechanism involving a dissociative transition state. One such inhibitor is synthesized by linking ATPγS to a peptide substrate analog via a two-carbon spacer. The compound acts as a high-affinity competitive inhibitor against both nucleotide and peptide substrates and demonstrates a slow off-rate. A crystal structure of this inhibitor bound to the tyrosine kinase domain of the insulin receptor confirms the key design features inspired by a dissociative transition state. It also reveals that the linker participates in the octahedral coordination of an active site magnesium ion.
Career Highlights
Abloogu has worked at prestigious institutions such as the Icahn School of Medicine at Mount Sinai and Johns Hopkins University. His research has focused on the development of innovative therapeutic agents that target specific kinases involved in cancer progression.
Collaborations
Some of his notable coworkers include Philip A. Cole and Keykavous Parang. Their collaborative efforts have contributed to advancing the understanding of kinase inhibitors and their potential applications in medicine.
Conclusion
Ararat Abloogu's work in the field of protein kinase inhibitors showcases his innovative spirit and dedication to advancing cancer therapeutics. His contributions are paving the way for new treatments that could significantly impact patient care.